This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Overexpression due to gene amplification is the preferred mechanism of HER2 upregulation in breast cancer, and the advent of trastuzumab, a humanized monoclonal antibody against the HER2 ...

Severance season two premieres tomorrow (January 17) on Apple TV+ with episodes airing weekly on the streaming platform with a total of 10 new instalments. The trailer for season two saw Mark S ...

"From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...